IX Biopharma Ltd
SGX:42C
Income Statement
Earnings Waterfall
IX Biopharma Ltd
Revenue
|
6.1m
SGD
|
Cost of Revenue
|
-4m
SGD
|
Gross Profit
|
2m
SGD
|
Operating Expenses
|
-8.6m
SGD
|
Operating Income
|
-6.6m
SGD
|
Other Expenses
|
-3m
SGD
|
Net Income
|
-9.6m
SGD
|
Income Statement
IX Biopharma Ltd
Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||
Revenue |
6
N/A
|
6
0%
|
6
+2%
|
6
+7%
|
6
+1%
|
7
+3%
|
3
-49%
|
2
-42%
|
0
-87%
|
(1)
N/A
|
0
N/A
|
1
+66%
|
1
+10%
|
1
+3%
|
1
+27%
|
1
+12%
|
2
+54%
|
2
+15%
|
14
+708%
|
14
+2%
|
4
-74%
|
6
+58%
|
6
+2%
|
|
Gross Profit | ||||||||||||||||||||||||
Cost of Revenue |
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(2)
|
(1)
|
(0)
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(4)
|
(4)
|
|
Gross Profit |
2
N/A
|
2
-7%
|
2
-1%
|
2
+32%
|
2
+8%
|
2
+1%
|
1
-45%
|
1
-46%
|
(0)
N/A
|
(1)
-237%
|
(0)
+50%
|
(1)
-31%
|
(1)
+3%
|
(1)
-25%
|
(1)
-54%
|
(1)
+42%
|
(0)
+41%
|
(0)
-9%
|
12
N/A
|
12
+3%
|
1
-91%
|
2
+120%
|
2
-13%
|
|
Operating Income | ||||||||||||||||||||||||
Operating Expenses |
(8)
|
(8)
|
(6)
|
(6)
|
(11)
|
(12)
|
(14)
|
(14)
|
(14)
|
(14)
|
(15)
|
(13)
|
(11)
|
(12)
|
(14)
|
(10)
|
(7)
|
(9)
|
(12)
|
(11)
|
(10)
|
(11)
|
(9)
|
|
Selling, General & Administrative |
(7)
|
(6)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(8)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(8)
|
(10)
|
(9)
|
(9)
|
(8)
|
(10)
|
(9)
|
(9)
|
(9)
|
(7)
|
|
Research & Development |
(6)
|
(6)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(6)
|
(8)
|
(8)
|
(7)
|
(6)
|
(4)
|
(3)
|
(3)
|
(2)
|
(3)
|
(3)
|
(3)
|
(2)
|
(3)
|
(3)
|
(2)
|
|
Other Operating Expenses |
4
|
4
|
5
|
6
|
2
|
2
|
0
|
(1)
|
2
|
0
|
0
|
1
|
1
|
(1)
|
(0)
|
1
|
4
|
2
|
1
|
1
|
1
|
1
|
1
|
|
Operating Income |
(7)
N/A
|
(6)
+10%
|
(4)
+29%
|
(4)
+11%
|
(9)
-123%
|
(10)
-15%
|
(13)
-28%
|
(14)
-10%
|
(14)
-3%
|
(15)
-7%
|
(15)
0%
|
(14)
+9%
|
(12)
+17%
|
(13)
-13%
|
(15)
-16%
|
(11)
+29%
|
(7)
+32%
|
(10)
-34%
|
0
N/A
|
1
+274%
|
(9)
N/A
|
(8)
+10%
|
(7)
+22%
|
|
Pre-Tax Income | ||||||||||||||||||||||||
Interest Income Expense |
(1)
|
(0)
|
(0)
|
(0)
|
1
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(2)
|
(0)
|
(0)
|
0
|
(0)
|
2
|
(2)
|
(5)
|
(6)
|
(1)
|
(2)
|
|
Non-Reccuring Items |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(8)
N/A
|
(6)
+21%
|
(4)
+28%
|
(4)
+10%
|
(8)
-89%
|
(10)
-32%
|
(13)
-27%
|
(14)
-9%
|
(15)
-10%
|
(15)
-1%
|
(16)
-1%
|
(14)
+8%
|
(13)
+7%
|
(13)
+0%
|
(15)
-16%
|
(10)
+32%
|
(8)
+28%
|
(8)
-9%
|
(1)
+85%
|
(4)
-231%
|
(16)
-280%
|
(10)
+38%
|
(8)
+14%
|
|
Net Income | ||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
0
|
(1)
|
|
Income from Continuing Operations |
(8)
|
(6)
|
(4)
|
(4)
|
(7)
|
(10)
|
(13)
|
(14)
|
(15)
|
(15)
|
(16)
|
(14)
|
(13)
|
(13)
|
(15)
|
(10)
|
(8)
|
(8)
|
(2)
|
(5)
|
(16)
|
(10)
|
(10)
|
|
Net Income (Common) |
(8)
N/A
|
(6)
+21%
|
(4)
+28%
|
(4)
+9%
|
(7)
-87%
|
(10)
-33%
|
(12)
-26%
|
(14)
-11%
|
(15)
-10%
|
(15)
0%
|
(16)
-2%
|
(4)
+77%
|
(3)
+17%
|
(3)
-3%
|
(5)
-70%
|
(10)
-100%
|
(8)
+28%
|
(8)
-9%
|
(2)
+79%
|
(5)
-161%
|
(16)
-239%
|
(10)
+38%
|
(10)
+0%
|
|
EPS (Diluted) |
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
0
N/A
|
-0.01
N/A
|
0
N/A
|
-0.01
N/A
|
-0.02
-100%
|
-0.02
N/A
|
-0.04
-100%
|
-0.03
+25%
|
-0.03
N/A
|
-0.02
+33%
|
-0.02
N/A
|
-0.02
N/A
|
-0.02
N/A
|
-0.01
+50%
|
-0.01
N/A
|
0
N/A
|
-0.01
N/A
|
-0.02
-100%
|
-0.01
+50%
|
-0.01
N/A
|